Traditional methods of diagnosing Alzheimer’s rely heavily on subjective cognitive assessments and symptomatic evaluation, which frequently miss the early, preclinical stages of the disease. Fastball EEG, by contrast, operates on a principle of passivity: participants are only required to view a rapid sequence of images while their brain’s electrical responses are recorded. This approach bypasses the need for active memory recall or instruction following, thereby delivering an unbiased and sensitive measure of recognition memory function that is both scalable and accessible.

The research team published their findings in the respected journal Brain Communications, detailing the performance of this technique in various settings, including real-world environments such as participants’ own homes. This is a crucial advance, as most neurological diagnostics necessitate specialized clinical facilities and trained personnel, factors which limit widespread, early screening efforts. The ability to administer Fastball outside of hospital or laboratory settings heralds a democratization of dementia diagnosis, enabling earlier interventions and monitoring.

Fastball works by detecting characteristic neural responses known as event-related potentials (ERPs), which are elicited when the brain recognizes previously seen images within a rapid visual stream. The technique quantifies these electrical markers using electroencephalography (EEG), a non-invasive and cost-effective brain imaging modality with millisecond temporal resolution. The researchers demonstrated that diminished ERP signatures correspond strongly with early cognitive decline, even identifying subtle impairments in individuals who later progressed towards dementia.

This technological breakthrough arrives at a critical juncture in Alzheimer’s treatment landscape. Recently approved disease-modifying therapies such as donanemab and lecanemab have shown exceptional promise in slowing progression when administered during the early symptomatic phases of Alzheimer’s. However, these treatments’ maximal efficacy hinges on timely diagnosis— a challenge given that an estimated one in three people with dementia in England remain undiagnosed. Fastball EEG’s ability to facilitate early, objective detection could bridge this diagnostic gap, improving patient outcomes through prompt therapeutic intervention.

The study’s lead investigator, Dr. George Stothart, a cognitive neuroscientist specializing in memory neuroscience, highlighted the urgency of uncovering Alzheimer’s disease in its nascent stages. Conventional cognitive tests tend to detect memory decline only after substantial neurodegeneration has occurred. Fastball’s passive design, requiring minimal participant engagement, offers a radically new avenue for screening large populations efficiently and objectively, mitigating biases and variability inherent in subjective assessments.

Crucially, this research validates the reliability and robustness of the Fastball EEG protocol in diverse environments, showing consistent detection of memory impairment across both controlled laboratory conditions and everyday settings. This paves the way for its practical implementation in primary care facilities, memory clinics, and home-based health monitoring. The portable and user-friendly nature of the technology further facilitates large-scale deployment, potentially revolutionizing population screening for cognitive decline.

From a neuroscientific perspective, the Fastball test encapsulates cutting-edge application of cognitive electrophysiology in clinical diagnostics. By precisely capturing early-stage aberrations in recognition memory circuitry, it provides a window into the neural substrates affected by Alzheimer’s pathology. This objective probe into brain function stands in contrast to the limitations of neuroimaging techniques which, though informative, are costly and less scalable for widespread early detection.

The implications of this study extend beyond diagnosis; continuous and accessible monitoring of memory performance could shape the future landscape of personalized medicine for neurodegenerative disorders. Patients at risk could be tracked longitudinally with repeated Fastball assessments, enabling dynamic adjustment of therapeutic strategies and early detection of cognitive decline progression. Additionally, such tools may enhance recruitment and stratification in clinical trials aiming to test novel Alzheimer’s therapies.

Financially supported by the Academy of Medical Sciences and dementia charity BRACE, this research exemplifies successful collaboration between academia and charitable organizations dedicated to conquering dementia. BRACE’s ongoing investment underscores the transformative potential of Fastball EEG in expanding diagnostic capabilities and delivering equitable access to cognitive health assessments.

Leading voices in dementia research have praised this work as a crucial stepping stone toward overcoming the daunting challenge of underdiagnosis. By offering a low-cost, portable, and accurate diagnostic tool, Fastball EEG could catalyze a global shift in dementia care, reducing the burden on healthcare systems by enabling preemptive measures, early treatment, and more targeted support for affected individuals and their families.

Looking forward, the research team aims to refine the Fastball protocol further and expand studies to larger, more diverse populations. Integration with wearable EEG devices and machine learning algorithms for automated data interpretation could further enhance the scalability and precision of this early detection method. This innovation not only holds promise for Alzheimer’s but could be adapted for monitoring other neurodegenerative and cognitive disorders, broadening its impact on neurological health worldwide.

In sum, the University of Bath’s development of the Fastball test represents a transformative fusion of cognitive neuroscience, clinical research, and technological innovation. It addresses a critical unmet need for early, objective, and accessible detection of memory impairment associated with Alzheimer’s disease, with the potential to alter clinical practices and improve countless lives globally.

Subject of Research: People

Article Title: A passive and objective measure of recognition memory in mild cognitive impairment using Fastball memory assessment

News Publication Date: 1-Sep-2025

References:

1. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial, [DOI/link]
2. Lecanemab in Early Alzheimer’s Disease, [DOI/link]
3. Primary Care Dementia Data, NHS England [DOI/link]

Image Credits: Credit BRACE Dementia Research

Keywords: Alzheimer disease; Neurodegenerative diseases; Diseases and disorders; Neurological disorders; Health and medicine; Human health; Psychological science; Cognitive psychology; Cognition; Cognitive function; Mental images

By employing a rigorous quasi-experimental methodology, the researchers compared pollution levels, health outcomes, and economic indicators from Greater London with similar areas across England not subject to these stringent emission controls. The results demonstrate a clear causative relationship between the introduction of LEZ and ULEZ and the marked decline in harmful airborne pollutants, particularly nitrogen dioxide (NO₂) and particulate matter with a diameter of 10 micrometers or less (PM10).

Quantitative data revealed that following the initial LEZ rollout, nitrogen dioxide levels dropped by 5.8%, and fine particulate matter decreased by 9.7%. The ULEZ, which represents the strictest low emission regulation globally, delivered even more substantial improvements, reducing NO₂ concentrations by 21% and PM10 by 15% within Central London when compared to control regions. Such reductions are not only environmentally significant but are closely correlated with tangible improvements in public health metrics.

One of the most striking findings of the study is the 18.5% reduction in sick leave among London workers, directly attributable to cleaner air. This decrease in absenteeism reflects a healthier workforce benefiting from diminished air pollution-related illness and stress. Additionally, respiratory conditions, which are notoriously exacerbated by poor air quality, saw a 10.2% decline after the implementation of the emission zones. The incidence of general health problems fell by 6.8%, concurrently supporting the evidence that air quality improvements bolster overall health.

The researchers also highlight an uplift in mental well-being among London residents living within the regulated zones. Self-reported measures of happiness, life satisfaction, and reduced anxiety levels suggest that air quality is intimately linked not just to physical health but also to psychological welfare. This holistic improvement in quality of life challenges urban policymakers to view environmental reforms as multi-dimensional interventions, capable of uplifting social and economic wellbeing.

Financially, the benefits are equally impressive. Annual savings in public health expenditure exceed £37 million, primarily through reductions in respiratory illnesses and the associated decrease in workforce absenteeism. These economic gains underscore the cost-effectiveness of the LEZ and ULEZ policies. Investment in emission control not only addresses environmental degradation but yields substantial returns by lowering healthcare costs and enhancing productivity.

Professor Eleonora Fichera, a leading economist involved in the study, elaborates on the broader implications of these findings. She emphasizes that transport policies focused on reducing vehicular emissions represent a smart, strategic approach to tackling some of the most pressing urban challenges. With the World Health Organization attributing 4.2 million premature deaths worldwide annually to air pollution, London’s experience offers a replicable model for other cities confronting similar public health crises.

The research was led by Dr. Habtamu Beshir, whose work underscores the integration of environmental policy with economic and social frameworks. His analysis demonstrates that clean air initiatives transcend ecological concerns; they are essential to creating sustainable urban ecosystems characterized by healthier populations and resilient economies. Dr. Beshir’s insights advocate for global adoption of stringent emission zones, reinforcing their role as a critical tool in the fight against pollution-induced morbidity and mortality.

Technically, the study’s strength lies in its comprehensive use of longitudinal data spanning multiple phases of the LEZ and ULEZ rollouts. This allowed for precise measurement of pollutant concentration changes before and after policy implementation, controlling for confounding variables through comparison with unaffected regions. The quasi-experimental design ensures the robustness of causality claims, bridging environmental science with health economics in a novel, data-driven manner.

Such an interdisciplinary approach provides policymakers with empirical evidence that investing in pollution control yields measurable benefits across public health, mental well-being, and economic productivity. It moves beyond traditional environmental metrics, highlighting the socio-economic dividends of sustainable urban governance. This fusion of data analytics and policy impact evaluation stands to influence future urban planning, especially in megacities battling traffic congestion and air quality challenges.

Furthermore, the findings contribute to the global body of knowledge linking environmental management with behavioral economics. Reduced pollution fosters healthier behaviors, improved workforce engagement, and enhanced life satisfaction, illustrating the feedback loops between environment, economic activity, and human psychology. By quantitatively substantiating these dynamics, the University of Bath’s study advances the argument for cleaner, greener cities as foundational to future urban resilience and prosperity.

In conclusion, the University of Bath’s research paints a compelling picture of how low emission zones operate as catalysts for positive change. Their success in Greater London demonstrates that thoughtful, evidence-based environmental policies can yield real-world health improvements and economic advantages. As cities worldwide grapple with climate change, urban pollution, and public health challenges, such findings underscore the urgent need to implement and expand similar clean air initiatives, ensuring sustainable, healthy futures for urban populations globally.

Subject of Research: Impacts of low emission zones on sick leave and mental well-being in Greater London

Article Title: “And Breathe Normally”: Impacts of low emission zones on sick leave and mental well-being

News Publication Date: 16-Apr-2025

Web References:

• Journal of Economic Behavior & Organization
• DOI: 10.1016/j.jebo.2025.106994

Keywords: Air pollution, Medical economics, Respiration, Environmental methods, Economics research, Environmental economics, Digital data, Environmental health, Mental health, Money, Environmental issues, Behavioral economics, Pollution control

The study conducted at the University of Bath’s Centre for Nutrition, Exercise and Metabolism, funded by innocent drinks, aimed to explore the precision of CGMs when measuring blood glucose responses to various fruit-based products. The research involved healthy volunteers, all non-diabetic and within a healthy body mass index (BMI) range. Participants were assessed using both a CGM device—specifically, the Abbott Freestyle Libre 2, widely available on the NHS—and the gold standard finger-prick blood test. By adopting two distinct measurement methods, the study sought to ascertain the extent of discrepancies between the CGM readings and traditional blood sugar metrics.

Notably, the findings were startling. The research revealed consistent overestimations by the CGM, with the device recording significantly higher blood sugar levels compared to the finger-prick method. This disparity became particularly pronounced when participants consumed smoothies. In this instance, the Abbott Freestyle Libre 2 indicated a glycaemic index (GI) of 69—a medium level—vastly overstating the actual results, which showed a much lower GI of just 53. These inaccuracies extend beyond smoothies; the study demonstrated that whole fruits were often misclassified as medium or high-GI foods by the CGMs, when in reality, they were classified as low-GI through more traditional testing.

Such misclassifications could have substantial implications for users, who might erroneously conclude that consuming fruits poses a risk of harmful blood sugar spikes. The potential consequences of these inaccuracies are particularly alarming, as CGMs were also found to exaggerate the duration that participants spent above the recommended blood sugar level thresholds. Reports indicated that CGMs could overestimate this duration by nearly 400%. Such significant inaccuracies risk inducing unnecessary anxiety in individuals who are, in fact, maintaining well-controlled blood glucose levels.

The study’s insightful conclusions challenge the long-held belief that the process of blending fruits into smoothies inherently raises their GI. Contrary to popular opinion, the research demonstrated that whether fruits are ingested whole or in blended form, their glycaemic index remains low. This is a critical finding, as it dispels the myth that smoothies are detrimental to blood sugar control and reassures consumers that these healthy options maintain their nutritional benefits when processed.

Professor Javier Gonzalez from the University of Bath, an expert in nutrition and health, emphasized the utility of CGMs for individuals with diabetes. Gonzalez stated that, despite the inaccuracies of CGMs, the ability to acquire any measurement is better than having none at all for those managing diabetic conditions. However, he raised caution for otherwise healthy individuals, asserting that reliance on such devices could foster unnecessary dietary restrictions or result in less healthy food choices. He advocated for traditional methods to assess blood sugar accurately and highlighted the importance of identifying the roots of the inaccuracies found within CGMs to enhance their future performance.

Professor Gonzalez pinpointed various factors contributing to the observed inaccuracies in CGMs. He noted that these devices measure glucose in the interstitial fluid surrounding cells, rather than directly in the bloodstream. This fundamental difference can lead to discrepancies in readings due to several variables, including time delays and blood flow. Additionally, the way glucose is distributed in the body can influence these measurements, highlighting the complexity of achieving precise readings through CGM devices.

To contextualize the potential impact of these findings, the study involved 15 healthy volunteers who ingested an innocent drinks fruit smoothie made from a blend of mangoes, passion fruit, and apples. This methodology allowed researchers to assess the blood sugar responses meticulously while contrasting CGM outputs with established, traditional testing methods. The insights gleaned from this research raise important considerations for any user looking to CGMs as a reliable gauge of dietary impact on blood sugar levels.

With CGMs increasingly marketed towards non-diabetics seeking to improve their health, understanding their limitations is crucial. Consumers must be educated about the potential inaccuracies and reassured of the benefits of traditional testing options. Organizations and nutritionists must facilitate this education to ensure that users can make informed decisions based on accurate data rather than misleading information from CGM devices.

In conclusion, while CGMs provide significant benefits for diabetes management, their application among healthy individuals requires scrutiny. The overestimations highlighted in the University of Bath’s research could lead to unnecessary dietary anxieties and restrictive habits among users who may not need to alter their consumption of fruits and related products. The findings serve as a reminder that while technology can offer insights into our health, it is vital to approach such data critically and complement it with traditional methods when accuracy is paramount.

Subject of Research: Accuracy of Continuous Glucose Monitors in Healthy Individuals
Article Title: Continuous glucose monitor overestimates glycemia, with the magnitude of bias varying by postprandial test and individual – A randomized crossover trial
News Publication Date: 26-Feb-2025
Web References: https://www.bbc.co.uk/news/articles/c1ddk1ddme5o, https://www.bath.ac.uk/research-centres/centre-for-nutrition-exercise-and-metabolism/, https://www.innocentdrinks.co.uk/home
References: DOI: 10.1016/j.ajcnut.2025.02.024
Image Credits: University of Bath

Keywords: Continuous Glucose Monitors, Blood Sugar Level, Glycaemic Index, Diabetes Management, Fruit Consumption, Nutritional Science, University of Bath, Health Technology, Dietary Choices, Accuracy of Measurements, Interstitial Fluid, Blood Flow Variability.